ABBOTT PARK, Ill., Dec. 18, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) will present at the 42nd annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 9, 2024. Robert B. Ford, chairman and chief executive officer, will present at 11 a.m. Central time.
A live webcast of the presentation will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com.
About Abbott
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 115,000 colleagues serve people in more than 160 countries.
Connect with us at www.abbott.com, on LinkedIn at www.linkedin.com/company/abbott-/, on Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews.
| Last Trade: | US$133.73 |
| Daily Change: | 1.08 0.81 |
| Daily Volume: | 4,048,584 |
| Market Cap: | US$232.690B |
August 29, 2025 July 17, 2025 July 08, 2025 June 16, 2025 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
